Point72 Hong Kong LTD Prothena Corp Public LTD CO Transaction History

Point72 Hong Kong LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $71,031 - $124,937	-3,125 Reduced 80.9%	738 $20,000
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $116,933 - $190,136	3,863 New	3,863 $141,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $13,643 - $23,736	-324 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $137,803 - $225,546	-2,859 Reduced 89.82%	324 $23,000
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $59,222 - $157,845	2,738 Added 615.28%	3,183 $164,000
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $4,895 - $12,566	445 New	445 $11,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $129 - $175	-13 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $124 - $162	13 New	13 $0

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.